USPTO serial 79404481
LUMIT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LADNER, CHRISOPHER G
- Law office
- TMO LAW OFFICE 112
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with LUMIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles Y. Park
Charles Y. Park NSIP LawP.O. Box 65745Washington, DC 20035United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical agents affecting peripheral nervous system; dietary fiber to aid digestion; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceutical preparations; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; eye drops; allergy medications; dietetic food substances, namely, plant-derived bioactive compounds, mitochondria-targeted supplements, and functional nutraceuticals for cardiovascular, immune, and metabolic health adapted for medical use; bath preparations for medical purposes; diagnostic agents for medical use; slimming tea for medical purposes; pharmaceutical compositions for the prevention and treatment of mitochondrial disorders, metabolic imbalances, cardiovascular diseases, immune dysregulation, cancer, fibrosis, and neurodegenerative diseases; pharmaceutical preparations for enhancing mitochondrial bioenergetics to support cardiovascular function, regulate immune responses, prevent and treat cardiac fibrosis, and improve vascular and metabolic health; pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis of mitochondrial disorders, cardiovascular diseases, immune dysregulation, cancer progression, neurodegenerative progression, and metabolic imbalances; analgesic balm; nutraceuticals for therapeutic purposes in the nature of mitochondrial energy restoration, immune system modulation, endothelial function support, and fibrosis attenuation; nutraceutical preparations for therapeutic and medical purposes in the nature of cardiovascular protection, oxidative stress regulation, immune system enhancement, and cellular metabolism optimization; pharmaceutical preparations for the treatment of parkinson's disease; antimicrobials for dermatologic use; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparation for skin care; pharmaceutical preparations for skin care; antihypertensives; anti-diabetic pharmaceuticals; anti-cancer preparations; anti-sarcoma preparations; anticoagulants; anti-cancer preparations in the nature of antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders of the respiratory organs; pharmaceutical preparations in the nature of pharmaceutical compounds for treating respiratory diseases and infections; pharmaceutical products for treating respiratory diseases; inhaled pharmaceutical preparations for the treatment of respiratory diseases and infections; pharmaceutical preparations for treating respiratory diseases and infections. | ACTIVE | — |
| 042 | Pharmaceutical drug development services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; Research and development of medicines. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 26, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 19, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 19, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 27, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 6, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 6, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 6, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 27, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 27, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 24, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 23, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 17, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |